InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Hits Estimates

InflaRx (NASDAQ:IFRX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.16), Zacks reports. The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million.

InflaRx Price Performance

Shares of IFRX traded up $0.03 during mid-day trading on Wednesday, hitting $1.68. The company's stock had a trading volume of 2,327,579 shares, compared to its average volume of 1,075,154. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.82. The firm has a 50-day moving average price of $1.38 and a 200 day moving average price of $1.18. The stock has a market capitalization of $112.78 million, a price-to-earnings ratio of -2.18 and a beta of 1.38.

Institutional Trading of InflaRx

Institutional investors have recently made changes to their positions in the stock. Woodline Partners LP acquired a new stake in InflaRx in the first quarter valued at approximately $766,000. Adage Capital Partners GP L.L.C. bought a new position in InflaRx during the second quarter worth $262,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. HC Wainwright initiated coverage on shares of InflaRx in a report on Tuesday, September 2nd. They set a "buy" rating and a $6.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a report on Wednesday, November 5th. Wall Street Zen lowered InflaRx from a "hold" rating to a "sell" rating in a research note on Saturday. Guggenheim lifted their price objective on InflaRx from $10.00 to $22.00 and gave the stock a "buy" rating in a report on Monday. Finally, Raymond James Financial reissued an "outperform" rating on shares of InflaRx in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $8.60.

Check Out Our Latest Stock Analysis on IFRX

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

Featured Articles

• Five stocks we like better than InflaRx
• With Risk Tolerance, One Size Does Not Fit All
• Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay
• How to Use Stock Screeners to Find Stocks
• Occidental Petroleum is a Buy in Q4 2025
• Best Energy Stocks - Energy Stocks to Buy Now
• 3 Beaten-Down Stocks With Rebound Potential This Earnings Season

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in InflaRx Right Now?

Before you consider InflaRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.

While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here